Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-05-14

FDA Approved: FLOLAN — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for FLOLAN (epoprostenol sodium) from GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FLOLAN (EPOPROSTENOL SODIUM)

Snippet

SUPPL AP for FLOLAN (EPOPROSTENOL SODIUM)